Eli Lilly's weight-loss drug Zepbound and diabetes medication Mounjaro are no longer in short supply. That could limit ...
The change will expand access to the diabetes and weight-loss drugs. But it will also complicate the future of compounded ...
After nearly two years, federal regulators announced the shortage of the active ingredient in Mounjaro and Zepbound has been ...
The roadmap suggests those with the greatest clinical need will get priority access, according to the NHS national medical ...
GLP-1 weight-loss drugs Mounjaro and Zepbound have been removed from the Food and Drug Administration's (FDA) shortage list. ...
The US Food and Drug Administration (FDA) has declared an end to the shortage of tirzepatide, the active ingredient in Eli ...
The NHS plans to roll out Mounjaro, a weight-loss jab that can help users lose up to a quarter of their body weight, making it more potent than Ozempic. Anna Magee explains how to choose the best opti ...
Tirzepatide was granted approval from the Medicines and Healthcare products Regulatory Agency last November, while NICE ...
The FDA confirmed Thursday that Eli Lilly has increased production of its blockbuster weight-loss drug Zepbound and type 2 ...
Eli Lilly’s juggernaut diabetes and obesity drugs Mounjaro and Zepbound have been erased from the FDA’s shortage list, ...
While Mounjaro was cleared for use in England last year, Lilly put its launch on hold until its pre-filled injection device, ...
The FDA has resolved Eli Lilly's tirzepatide shortage, but localized supply issues persist. Meanwhile, Hims & Hers Health's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback